From the Journals
Feature

GLP-1 drugs pose no cancer risk, review finds

A large systematic review and meta-analysis was limited by a median follow-up of 70 weeks.

Share

A systematic review and meta-analysis highlighted that glucagon-like peptide-1 receptor agonists (GLP-1RAs) do not significantly increase overall cancer risk after 70 weeks of follow-up, as stated by Cho-Han Chiang, MD, from Harvard Medical School. While early studies raised concerns about links to certain cancers, recent data suggests consistency in reassuring results regarding cancer risk. Ongoing monitoring and longer-term trials are essential to clarify the long-term safety of GLP-1RAs, especially for those with a history of cancer.

Original Source(s)

GLP-1 drugs pose no cancer risk, review finds

A large systematic review and meta-analysis was limited by a median follow-up of 70 weeks.

  • by Doug Brunk

  • December 11, 2025

  • 4 min

Related Content

Liver Supplements: Big Sales, Limited Evidence

Researchers evaluate how popular liver cleanse products are formulated and promoted in the US online marketplace.

Gut Bacteria Linked to Insulin Resistance

Study highlights how 'Proteobacteria and bile acids in the gut negatively impact insulin sensitivity,' offering potential therapeutic targets across the microbiome-gut-adipose-liver axis.

Juice Cleanses May Alter Oral Microbiota

Popular juice-only diets may negatively impact oral and gut microbiomes.